A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms CANTOS; CANTOS sub-study 1; CANTOS sub-study 2
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Jun 2018 Results of a secondary analysis assessing the relationships between serum urate,canakinumab, and incidence rates for gout and cardiovascular events, presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 19 Mar 2018 Planned End Date changed from 2 Dec 2019 to 2 Mar 2020.
    • 03 Mar 2018 Results assessing the role of Canakinumab for the prevention and management of diabetes, published in the Journal of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top